September 17, 2020
Premera will be extending cost share waivers for COVID-19 treatment through December 31, 2020. This means that members will not pay a cost share requiring treatment for COVID-19. FDA-approved diagnostic testing and the related provider visit cost share waivers are extended through November 15, 2020 in compliance with federal rules. All other treatments and services including hospitalizations will be subject to the usual benefits and cost shares. We’ll continue to evaluate guidance and the scope of COVID-19 and adjust as needed.
As always, check member eligibility and benefits for each visit.